Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 VTU Technology and Biomay Sign License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

VTU Technology and Biomay Sign License Agreement

Biomay to apply VTU Pichia strains for the production of recombinant allergens

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

VTU Technology and Biomay, two leading Austrian biotech companies, have entered into a licensing agreement for the production of recombinant allergens.

VTU Technology, currently offering a broad and comprehensive Pichia pastoris expression platform, grants Biomay access to VTU´s Pichia pastoris protein expression technology. Biomay, a global leader in allergy immunotherapy, will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. Under the terms of the agreement, VTU Technology will receive royalties based on Biomay´s worldwide sales of the recombinant allergens.

VTU’s Pichia platform enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes. “VTU´s Pichia platform has already been utilized for the production of a wide range of different recombinant proteins with licenses granted to companies from diverse industries. We are very happy to extend this list of partnerships to the allergen space by our agreement with Biomay,” said Thomas Purkarthofer, head of business development, VTU Technology.

“For Biomay, this technology cooperation with VTU is an excellent option for manufacturing of allergens being difficult to express,” said Hans Huber, chief operating officer, Biomay. “Thereby, we recently managed to produce and offer for sale the major allergen from ragweed pollen, Amb a 1, as a recombinant product.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics